Skip to main content

Table 1 Clinical evaluation of anti-IGF-IR or anti-IGF1/2 mAbs in cancer patients

From: Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

Drug

Combination

Cancer type

Phase

Participants

Response

Ref. or trial ID

Ganitumab

None

Ewing sarcoma; desmoplastic small round cell tumors

2

38

PR, 16%; SD > 24 weeks: 49%.

[144] NCT00563680

Ganitumab

Doxorubicin, etoposide or radiotherapy

Metastatic Ewing sarcoma

3

330

This trial is still ongoing.

NCT02306161

Ganitumab

Palbciclib (CDK4/6 inhibitor)

Ewing sarcoma

2

18

This trial is still ongoing.

NCT04129151

Ganitumab

Dasatinib

Rhabdomyosarcoma

1/2

40

This trial is still ongoing.

NCT03041701

Ganitumab

Panitumumab

Colorectal cancer

1/2

142

ORR, 22%. No improvement, compared to panitumumab plus placebo.

[145] NCT00788957

Ganitumab

None

Recurrent platinum-sensitive ovarian cancer

2

61

Objective response rate, 1.6% (95%CI 0-8.8%); CBR, 1.7% (95% CI, 0-8.9%); PFS, 1.94 months (95% CI 1.45-2.1 months).

NCT00719212

Ganitumab

Gemcitabine

Metastatic pancreatic cancer

3

640

No improvement on OS.

[146] NCT01231347

Ganitumab

Metformin

Breast cancer

2

Estimated enrollment of 4000

This trial is still ongoing.

NCT01042379

Figitumumab

None

Ewing sarcoma

2

107

PR, 14.02%; SD, 23.36%.

[147] NCT00560235

Figitumumab

None

Ewing sarcoma

1

16

CR, 6.25%; PR, 6.25%; SD, 37.5%.

[148] NCT00474760

Cixutumumab

None

Refractory solid tumors

2

36

PR, 8.33%; SD, 13.89%.

[149]

Cixutumumab

None

Previously treated advanced or metastatic rhabdomyosarcoma, leiomyosarcoma, adipocytic sarcoma, synovial sarcoma or Ewing family of tumors

2

113

12-week PFR, 12% for rhabdomyosarcoma, 14% for leiomyosarcoma, 32% for adipocytic sarcoma, 18% for synovial sarcoma and 11% for Ewing family of tumors.

Median PFS, 6.1 weeks for rhabdomyosarcoma, 6.0 weeks for leiomyosarcoma, 12.1 weeks for adipocytic sarcoma, 6.4 weeks for synovial sarcoma and 6.4 weeks for Ewing family of tumors.

[150]

Cixutumumab

None

Metastatic melanoma of the eye

2

18

CR, 0; PR, 0; SD, 50%; PFS, 2.21 weeks (95% CI 0–23.2); OS, 59.71 weeks (95% CI 0–109.6)

NCT01413191

Cixutumumab

Temsirolimus

Bone and soft tissue sarcoma

2

159

PR, 2.52%; SD, 61.64%; PD,35.85%

NCT01016015

MK-0646

Gemcitabine, Erlotinib

Advanced pancreatic carcinoma

1/2

45

PFS, 1.8 months (95% CI 1.8–9.7) for MK plus gemcitabine (arm A), 1.8 months (95% CI 1.7–5.5) for MK plus gemcitabine and erlotinib (arm B), and 1.9 months (95% CI 1.8–5.4) for gemcitabine and erlotinib (arm C); OS, 10.4 months (95% CI 3.9–18.9) for arm A, 7.1 months (95% CI 5.2–20.0) for arm B, and 5.7 months (95% CI 4.0–9.5) for arm C.

[151] NCT00769483

Xentuzumab

Everolimus, exemestane

Breast cancer

2

100

This trial is still ongoing.

NCT03659136

Xentuzumab

Everolimus, exemestane

Breast cancer

1b/2

164

This trial is still active.

NCT02123823

Xentuzumab

None

Advanced solid tumors

1

21

This trial is still active.

NCT02145741

  1. CR complete response, CBR clinical benefit rate, ORR overall response rate, OS overall survival, PFR progression-free survival rate. PFS progression-free survival, PR partial response, SD stable disease, Trial ID registered number at ClinicalTrials.gov